Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

ClinicalTrials.gov ID: NCT01068600

Public ClinicalTrials.gov record NCT01068600. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients With Chronic Obstructive Pulmonary Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.

Study identification

NCT ID
NCT01068600
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis
Industry
Enrollment
318 participants

Conditions and interventions

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2010 (Type not available)
Primary completion
Jun 2010 (Actual)
Completion
Not listed
Last update posted
Aug 19, 2011

Started 2010

United States locations

U.S. sites
54
U.S. states
22
U.S. cities
49
Facility City State ZIP Site status
Novartis Investigative Site Anniston Alabama 36207-5710 —
Novartis Investigative Site Jasper Alabama 35501 —
Novartis Investigator Site Glendale Arizona 85306 —
Novartis Investigator Site Phoenix Arizona 85006 —
Novartis Investigator Site Fullerton California 92835 —
Novartis Investigator Site Los Angeles California 90048 —
Novartis Investigator Site Los Angeles California 90095 —
Novartis Investigator Site Riverside California 92506 —
Novartis Investigative Site Clearwater Florida 33756 —
Novartis Investigative Site Clearwater Florida 33765 —
Novartis Investigative Site Hollywood Florida 33021 —
Novartis Investigative site Miami Florida 33145 —
Novartis Investigative Site Tampa Florida 33603 —
Novartis Investigative Site Winter Park Florida 32789 —
Novartis Investigative Site Atlanta Georgia 30342 —
Novartis Investigator Site Normal Illinois 61761 —
Novartis Investigator Site Iowa City Iowa 52242 —
Novartis Investigative Site Madisonville Kentucky 42431 —
Novartis Investigator Site Baton Rouge Louisiana 70808 —
Novartis Investigator Site Opelousas Louisiana 70570 —
Novartis Investigator Site Saint Charles Missouri 63301 —
Novartis Investigator Site St Louis Missouri 63141 —
Novartis Investigator Site Lincoln Nebraska 68510 —
Novartis Investigator Site Omaha Nebraska 68114 —
Novartis Investigator Site Omaha Nebraska 68134 —
Novartis Investigator Site Henderson Nevada 89014 —
Novartis Investigator Site Las Vegas Nevada 89119 —
Novartis Investigative Site Cherry Hill New Jersey 08003 —
Novartis Investigator Site Albuquerque New Mexico 87108 —
Novartis Investigative Site Charlotte North Carolina 28207 —
Novartis Investigative Site Raleigh North Carolina 27607 —
Novartis Investigative Site Shelby North Carolina 28152 —
Novartis Investigative Site Canton Ohio 44718 —
Novartis Investigator Site Cincinnati Ohio 45242 —
Novartis Investigative Site Columbus Ohio 43213 —
Novartis Investigative Site Columbus Ohio 43215 —
Novartis Investigator Site Marion Ohio 43302 —
Novartis Investigator Site Eugene Oregon 97404 —
Novartis Investigator Site Medford Oregon 97504 —
Novartis Investigative Site Cumberland Rhode Island 02864 —
Novartis Investigative Site Pawtucket Rhode Island 02860 —
Novartis Investigative Site Charleston South Carolina 29407 —
Novartis Investigative Site Charleston South Carolina 29412 —
Novartis Investigative Site Easley South Carolina 29640 —
Novartis Investigative site Greenville South Carolina 29615 —
Novartis Investigative Site North Charleston South Carolina 29406 —
Novartis Investigative Site Spartanburg South Carolina 29303 —
Novartis Investigative Site Union South Carolina 29379 —
Novartis Investigator Site Arlington Texas 76012 —
Novartis Investigator Site Dickinson Texas 77539 —
Novartis Investigator Site El Paso Texas 79903 —
Novartis Investigator Site McKinney Texas 75069 —
Novartis Investigative Site South Burlington Vermont 05403 —
Novartis Investigative Site Richmond Virginia 23229 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01068600, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 19, 2011 · Synced Oct 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01068600 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →